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Abstract: Aptamers are oligonucleotide ligands, either RNA or ssDNA, selected for   
high-affinity binding to molecular targets, such as small organic molecules, proteins or 
whole microorganisms. While reports of new aptamers are numerous, characterization of 
their specific interaction is often restricted to the affinity of binding (KD). Over the years, 
crystal structures of aptamer-protein complexes have only scarcely become available.   
Here we describe some relevant technical issues about the process of crystallizing   
aptamer-protein complexes and highlight some biochemical details on the molecular basis 
of selected aptamer-protein interactions. In addition, alternative experimental and 
computational approaches are discussed to study aptamer-protein interactions. 
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1. Introduction 
Aptamers are single-stranded DNA (ssDNA) or RNA oligonucleotides selected to bind specifically 
to a predefined target. Since their initial development two decades ago [1,2] the field of aptamer 
research has matured. During these years, numerous aptamers, recognizing a wide range of targets, 
have become available, such as, for example, those binding small organic molecules [3–5], peptides 
and proteins [6,7], or even whole microorganisms [8,9]. 
The systematic evolution of ligands by exponential enrichment (SELEX) is the most common 
method by which aptamers are enriched from large pools of randomized DNA or RNA   
(10
14–10
15 variants), in an iterative process by applying several subsequent selection rounds. Selection 
is initiated by exposing the oligonucleotides to a target that is either coupled to a matrix (e.g., magnetic 
beads or column material) or already present on a surface (e.g., cell surface). Subsequently,   
non-binding oligonucleotide molecules are washed away, and the bound molecules are recovered, 
amplified by PCR or RT-PCR, and made single-stranded again. Several variations of the SELEX 
procedure have been successfully applied over the years [10]. 
In many cases, the minimal sequence required for efficient target binding is smaller than the length 
of the oligonucleotides that comprise the pool. In order to increase specificity and to reduce synthesis 
costs of the selected aptamers, the minimal binding sequence should be identified. Approaches to 
identify the minimal binding sequence can be straightforward when a conserved nucleotide motif or 
secondary structure is enriched [11,12]; otherwise, identifying the minimal binding sequence can be 
more laborious [13–15]. 
Aptamer-target interactions depend on the nature of the target and on the nucleotide sequence and 
3D structure of the aptamer. Aptamers occur in a wide variety of structural shapes, such as hairpins, 
bulges, pseudoknots and G-quadruplexes [10]. Due to these various structural shapes, aptamers can 
bind their targets by hydrogen bonds, hydrophobic interactions, van der Waals interactions, aromatic 
stacking or, in most cases, a combination thereof [16]. 
Crystal structures of aptamer-target complexes provide very detailed information on the 
interactions; they are therefore crucial for a thorough understanding of the aptamer-target binding 
mode. However, obtaining crystal structures of aptamer-target complexes has proven difficult, and 
only a few co-crystal structures have become available over the years (Table 1). Besides X-ray 
crystallography, also other techniques, such as nuclear magnetic resonance (NMR), surface plasmon 
resonance (SPR), analysis using a quartz crystal microbalance (QCM) [17], isothermal titration 
calorimetry (ITC), Dynamic light scattering (DLS), circular dichroism (CD) [18] and small-angle   
X-ray scattering (SAXS) [12,19], have been used to study aptamer-target binding. Knowledge on the 
target-binding mode of newly described aptamers, however, is generally restricted to the affinity   
of binding. 
In this review, relevant technical issues and difficulties in the process of crystallizing aptamer-protein 
complexes are described. In addition, we will highlight some successful examples. Besides X-ray 
crystallography, several alternative approaches to investigate the molecular basis of aptamer-target 
interactions will be briefly discussed as well. 
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Table 1. Structures of aptamer-target complexes in the PDB database. 
Target  DNA/RNA  PDB entry code  Ref. 
Aptamer-protein complexes       
von Willebrand Factor Domain A1  DNA  3HXO 3HXQ  [20] 
Alpha-thrombin (human)  DNA  1HUT  [21] 
Alpha-thrombin (human)  DNA  1HAO 1HAP  [22] 
Alpha-thrombin (human)  RNA  3DD2  [23] 
Alpha-thrombin (human)  DNA  3QLP  [24] 
NF-κB(p50)2 RNA  1OOA  [25] 
NF-κB P50-RelB  DNA  2V2T  [26] 
YmaH (Hfq)  RNA  3HSB 3AHU  [27] 
a human IgG  RNA  3AGV  [28] 
Enterobacterio phage MS2 coat protein complex  RNA  6MSF  [29] 
Enterobacterio phage MS2  RNA  5MSF 7MSF  [30] 
Enterobacterio phage MS2  RNA  1U1Y  [31] 
Aptamer-small molecule complexes      
Malachite green  RNA  1F1T  [32] 
Vitamin B12  RNA  1ET4 1DDY  [33] 
Streptomycin RNA  1NTB  1NTA  [34] 
Biotin RNA  1F27  [35] 
2. Structure Determination 
Currently, the three-dimensional structures of many proteins, nucleic acids (e.g., riboswitches) and 
other biological molecules have been determined. The only methods that can provide atomic resolution 
structures are NMR spectroscopy, electron microscopy (electron crystallography) of two-dimensional 
(2D) crystals, and X-ray crystallography. Each of these methods has its advantages and limitations.  
In particular, NMR methods for determining high-resolution structures are largely limited to relatively 
small molecules (<30–40  kDa), due to complexity of the data [36,37]. By comparison, X-ray 
crystallography can solve structures of arbitrarily large molecules, but it requires crystals that provide 
suitable quality diffraction data. Screening for conditions that yield well diffracting crystals is still a 
trial and error method and often requires a significant amount of effort [38]. The chance of obtaining 
well-ordered 2D crystals for electron crystallography is higher, when compared to obtaining 3D 
crystals required for X-ray crystallography; however, structure determination and data processing from 
2D crystals is still labor intensive and time consuming [39]. 
While providing very detailed information, crystal structures of aptamer-protein complexes have 
only scarcely become available. Here, we would like to describe some relevant technical issues in the 
process of crystallizing aptamer-protein complexes and highlight those parameters that make 
crystallization especially challenging. 
  Int. J. Mol. Sci. 2012, 13  10540 
 
 
2.1. Nucleic Acid Parameters 
Several features of DNA or RNA play important roles in the process of co-crystallization. Apart 
from purity, the length and the ends (blunt or sticky) are also factors that must be explored when 
crystallizing nucleic acid-protein complexes. 
Perhaps one of the most significant variables is the length of the nucleic acid. A general rule in 
protein-nucleic acid crystallization is to identify a sequence of minimal length that binds tightly to the 
protein [40,41]. On the one hand, oligonucleotides that are too short will destabilize the complex, as it 
might limit the number of potential interactions between nucleic acid and protein, but on the other 
hand it may improve crystal quality, as it will reduce flanking regions that could disturb crystal 
contacts. Consequently, determining the minimal binding sequence of an aptamer should be considered 
essential. Although this is not always straightforward and can be time consuming, removing nucleotides 
that are unnecessary for target binding will prevent them from potentially disturbing crystal contacts. 
In addition to blunt-ended nucleic acids, single- or double-base overhangs (sticky ends) are 
commonly explored when crystallizing complexes containing DNA or RNA [40]. It is often observed 
in crystals that sticky ends form crystal contacts by base-paring with complementary sticky ends, 
forming a pseudo-continuous double helix. In order to allow the best end-to-end packing, the 
overhanging bases of one strand should be complementary to the overhanging bases of the opposite 
strand [41]. Nevertheless, this may not be easily applicable to aptamers, because sticky ends could 
disrupt the tertiary structure, and hence abolish binding, of the aptamer. It has been observed, however, 
that the 5′ extensions from two molecules of the vitamin B12 RNA aptamer form a crystal contact by 
creating a six-base-pair duplex with two stacked adenosine–adenosine pairs [33] (Figure 1). 
Figure 1. Crystal contacts between two vitamin B12 aptamers. The six-base-pair duplex 
between two vitamin B12 aptamers consists of two stacked adenosine–adenosine pairs 
(1ET4) [25]. Aptamers shown in blue and green, vitamin B12 in yellow. 
 
It may also be critical to have highly purified DNA or RNA to obtain well-ordered crystals of a 
protein-nucleic acid complex [41]. The most common methods for purifying synthesized 
oligonucleotides for use in crystallization experiments are anion exchange chromatography and Int. J. Mol. Sci. 2012, 13  10541 
 
 
purification from polyacrylamide gels (PAGE). Because results of purification can vary slightly, it is 
sometimes desirable to further treat the purified oligonucleotide, for instance by dialyzing against an 
appropriate buffer. 
RNA synthesis is relatively expensive; if no modified nucleotides are required, it could be cheaper 
and perhaps more convenient to transcribe the RNA from a DNA template. When more stable RNAs 
are required, one could order chemically synthesized RNA aptamers, in which all or specific uridines 
and cytidines are 2′-fluoro-modified. In some cases, these modified nucleotides have been used during 
both aptamer selection and crystallization; e.g., [23,42]. 
2.2. Protein Parameters 
A general requirement for crystallization experiments is that the protein needs to be homogeneous, 
i.e., highly pure (>98%) and in a low polydispersity state [43]. DLS is a commonly used technique to 
measure the polydispersity of a protein sample. Other parameters that should be established before 
setting up crystallization screens are the stability of the protein in different buffers, and whether the 
protein is correctly folded (CD spectroscopy) and active (activity measurements). 
2.3. Protein: Aptamer Ratio 
It is good practice to try several protein:aptamer molar ratios. In crystallization experiments, protein 
and DNA are usually mixed at 1:1.2 to 1:1.5 molar ratios with DNA in excess [41,43]. The principle 
behind this ratio is that the concentrations of protein and DNA are frequently rough estimations and 
DNA could possibly not saturate all binding sites on the protein. Our advice is, therefore, to use similar 
ratios when setting up crystallization experiments of protein-aptamer complexes. 
2.4. Crystallization Screens 
Screens for obtaining crystals should include a wide variety of crystallization conditions. 
Nowadays, many commercial screens are available from companies such as Hampton Research, 
Emerald BioSystems, Molecular Dimensions, Jena Bioscience and Qiagen; these also include screens 
specific for crystallizing nucleic acids and nucleic acid complexes. The commercial screens are 
undoubtedly the easiest way to initiate the first crystallization trials. For more elaborate information on 
protein crystallization, see [38,43,44]. For more elaborate information on RNA and sample preparation 
for crystallization of RNA and RNA-protein complexes in particular, see [45–47]. 
In general, for nucleic acid crystallization, it is favorable to use polyethylene glycol (PEG) or   
2-methyl-2,4-pentanediol (MPD) as precipitants, rather than high salt, because high salt may disrupt 
charged interactions between protein and nucleic acid. It is not possible to predict which screen will 
result in crystal formation, because many factors influence crystallization; variables include pH, ionic 
strength, temperature, protein concentration, the presence of various salts, ligands or additives, the type 
of precipitant and the crystallization method (hanging drop, sitting drop, dialysis, etc.) [38,44].  
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3. Examples from Literature 
Over the years, only a limited number of crystal structures of aptamer-protein complexes have 
become available (Table 1), but they have provided a wealth of information. Here two aptamer-protein 
complexes are described that have been successfully crystallized. 
3.1. Aptamer-Thrombin Complex 
Thrombin is a trypsin-like serine protease with an important role in hemostasis, by converting 
soluble fibrinogen into insoluble fibrin strands. Shortly after the initial development of SELEX, 
thrombin-binding DNA aptamers were described [48], providing the first example of DNA binding to 
a protein normally not involved in DNA binding. The year after thrombin binding aptamers had first 
been described, a crystal structure of the thrombin-aptamer complex became available. It was obtained 
using a reservoir solution of 25%–30% (v/v) PEG 8000, 375 mM NaCl, 0.5 mM NaN3 and 50 mM 
sodium phosphate at pH 7.3, which was also used for the crystallization of a thrombin-hirugen 
complex [21,49]. The crystal used for data collection grew in 2 months and diffracted to about 2.9 Å, it 
belongs to orthorhombic space group P212121. In the same year, an NMR solution structure [50,51] 
became available for the thrombin-aptamer complex as well. The crystal structure and NMR solution 
structure revealed that the core of the thrombin-binding aptamers is formed by two stacked   
G-quadruplexes (Figure 2a), although the crystal and NMR solution structure show different 
topologies of the G-quadruplex [52]. It was also shown that the aptamer binds to exosite I of thrombin 
(Figure 2b). Recently, another crystal structure of a thrombin-aptamer complex has been published 
(crystallized at 20 °C using 20% (w/v) PEG 20,000, 200 mM ammonium sulfate, 3% (v/v)  
n-propanol, 100 M sodium acetate at pH 5.8). It contains a modified thrombin binding aptamer that 
binds thrombin with higher affinity [24].  
Figure 2. (a) Double G-quadruplex shown in gold, loops in blue; (b) Thrombin aptamer 
bound to exosite 1 (magenta) of thrombin (1HUT) [32]. 
 
(a) (b) Int. J. Mol. Sci. 2012, 13  10543 
 
 
3.2. Anti-IgG Fc RNA Aptamer 
Recently, the 2.15 Å resolution crystal structure of the anti-Fc RNA aptamer in complex with the Fc 
fragment of a human IgG1 antibody (hFc1) was elucidated [28]. In most cases, RNA aptamers bind to 
their target proteins predominantly via electrostatic interactions between the negatively-charged 
phosphate backbones and positively-charged surface residues of proteins. To this end, the interaction 
between this aptamer and hFc1 is an exception, as it mainly consists of van der Waals contacts and 
hydrogen bonds, rather than electrostatic forces. The structure also revealed other interesting features. 
The RNA structure in the complex diverges greatly from its predicted secondary structure; it changes 
its conformation to one that structurally fits to hFc1 (Figure 3). The aptamer–hFc1 interaction is 
stabilized by a calcium ion and, therefore, binding and release of the aptamer can be controlled by 
either chelation or addition of calcium. 
Figure 3. Two RNA aptamers (gold) bound to the Fc domain of human IgG. Residues 
binding the aptamer are shown in magenta, calcium ions are shown as red spheres   
(3AGV) [37]. 
 
Crystals of the RNA aptamer in complex with hFc1 were grown by sitting-drop vapor   
diffusion using a reservoir solution containing 0.1 M Tris–HCl buffer (pH 8.0), 20% (w/v) PEG 1000 
and 0.2 M calcium acetate. [42]. The RNA aptamer was chemically synthesized containing   
2'-fluoropyrimidines and purified by PAGE. NMR analysis showed that the interaction between the Fc 
fragment and the aptamer has a 1:2 (Fc fragment:aptamer) stoichiometry [53]. Consequently, the 
aptamer was mixed with the Fc fragment in a molar ratio of 1:2.2 (Fc fragment:aptamer) for 
crystallization. The crystals belong to the space group P21212 and diffracted to 2.15 Å. Interestingly, 
crystal quality was improved by applying a solution stirring technique [54]. 
4. Crystallization of a Streptavidin-Aptamer Complex 
In previous work, we described the kinetic and stoichiometric characterization of streptavidin-binding 
aptamers [12]. In order to gain more insight into the molecular basis of the streptavidin-aptamer Int. J. Mol. Sci. 2012, 13  10544 
 
 
interaction, crystallization screens of the complex were conducted. Here, as an example, we will 
briefly describe our crystallization trials and the results obtained. 
For our initial crystallization experiments, we used the commercially available crystallization 
screens JCSG+ Suite (Qiagen) and Crystal Screen & Crystal Screen 2 (Hampton Research, CA, USA). 
Streptavidin and aptamer (Figure S1) were mixed in a ratio of 1 streptavidin tetramer to 5 aptamers. 
For further experimental details, see the Supplementary text. Crystals of sufficient quality for data 
collection (Figure 4) were obtained from a high salt condition (2.0 M ammonium sulfate and 5% (v/v) 
2-propanol), not containing PEG or MPD. Analysis of the 1.9 Å resolution structure showed the 
presence of extra electron density in the biotin-binding pocket, but this density was too small to have 
originated from an aptamer (Figures S2 and S3, for refinement statistics see Table S1). 
Figure 4. Crystal used for data collection. The crystal was obtained by vapor diffusion 
against a reservoir solution consisting of 2.0 M ammonium sulfate and 5% (v/v) 2-propanol 
(Crystal screen 2 condition 5). 
 
In a second series of crystallization experiments, we used the Natrix & Natrix 2 screens (Hampton 
Research, CA, USA), which contain conditions more dedicated towards crystallization of nucleic acids 
and protein-nucleic acid complexes. Streptavidin and aptamer were mixed in a ratio of 1 tetramer to 
2.2 aptamers on the basis of mass-spectrometry [12]. Although recently the use of chromophoric 
ligands was proposed to visually screen co-crystals of putative protein-nucleic acid complexes [55], we 
choose to conduct the crystallization screens in triplicate, using (i) streptavidin-aptamer complex,   
(ii) only streptavidin and (iii) only aptamer. In four conditions, crystals were obtained for both the   
streptavidin-aptamer complex and streptavidin alone. Crystals of the complex differed largely in size 
and shape from those of streptavidin only (Table S2), whereas no crystals grew in the same conditions 
containing only aptamer (pictures not shown). This indicates that the aptamer has a major effect on the 
crystallization process. Unfortunately, none of the crystals from the streptavidin-aptamer mix were 
suitable for data collection; they were either microcrystalline needles (1D) or plates (2D), and therefore 
it remains to be established whether they contain aptamer or not. 
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5. Alternative Methods of Investigating Aptamer Target Interactions 
Besides X-ray crystallography, alternative techniques exist to investigate the molecular basis of 
aptamer-target interactions. When used individually, these methods do perhaps not provide as much 
detailed information as a crystal structure, and they are probably not as visually appealing. However, 
using a combination of complementary techniques may still provide very detailed information on the 
interaction. Together, these techniques could be considered an alternative to X-ray crystallography, for 
instance, when crystallization trials fail to produce well diffracting crystals, or when no adequate 
equipment or expertise is available to conduct crystallization trials. Moreover, some of these 
techniques may provide information on the dynamics of complex formation, whereas crystallography 
gives a time- and position-averaged image. Since bioinformatics and experimental approaches are 
generally complementary, both will be discussed. 
5.1. Computational Approaches 
The sequence of an oligonucleotide, and the intramolecular base-pairing that this sequence enables, 
largely defines the 3D-structure of the oligonucleotide. Base-paired regions in the 3D-structure of the 
oligonucleotide are thought to act as stabilizers, allowing loops and bulges to position themselves in 
ways suitable for target interaction [56]. The nucleotide composition of distinct aptamers that bind the 
same target can vary strongly, particularly in the base-paired regions; however, the overall structure 
could remain largely similar [11,12,57]. In other words, structural elements shared between 
oligonucleotides might therefore not be easily visible from primary sequence alignments. In addition, 
defining the boundaries of the minimal sequence required for target binding is not straightforward. For 
these reasons, identifying a recurring structure, within a number of sequenced oligonucleotides of an 
enriched pool, can be challenging if only sequence alignments are used. 
Secondary structure predictions of clones in enriched pools may reveal recurring structural features, 
at any position and with deviating primary structures of oligonucleotides. These predictions could also 
be useful tools for identifying the minimal binding sequence. Most popular secondary structure 
prediction programs, including mfold [58], may be of limited value as they can only predict relatively 
simple hairpin structures. For the analysis of more complex aptamer structures, dedicated programs 
should be used, e.g., for the prediction of pseudoknots [59] and G-quadruplexes [60]. 
Besides secondary structure prediction, software has been developed to predict tertiary structures, 
varying from ab initio modeling to approaches requiring detailed information on base pairing and other 
interactions [61]. Such software has not frequently been used in aptamer research, partly because these 
programs often do not provide a single prediction, but rather give numerous possibilities that each have 
to be scored for their relevance. For example, the MC-Fold and MC-Sym pipeline [62] that we have 
previously used for the generation of a 3D-model of a streptavidin binding aptamer, provided   
57 widely different structural models [12]. Eventually a prediction was selected by comparing 
theoretical scatter of the predicted models with experimental SAXS data of the aptamer. A manual fit 
of the aptamer model onto a streptavidin crystal structure [12] showed that the aptamer could 
physically occupy two biotin-binding sites, and that it probably interacts with the loops that normally 
cover the biotin-binding pocket. This would explain the stoichiometry (2 aptamers per 1 streptavidin Int. J. Mol. Sci. 2012, 13  10546 
 
 
tetramer) and the presence of two distinct regions in the aptamer that are both essential for   
binding [12]. Although this modeling approach requires much more effort than standard secondary 
structure predictions, it can provide valuable information on the aptamer binding site and on the parts 
of the aptamer and the target protein that are involved in the interaction. 
5.2. Experimental Approaches 
As mentioned above, one of the requirements for the initiation of crystallization experiments with 
aptamer-protein complexes is establishing the minimal binding sequence of the aptamer. As described, 
this can be relatively easy if a recurring sequence or structural motif is found, but binding should still 
be confirmed. 
Alternatively, a full length aptamer may be shortened from either the 5' or 3' end to various lengths, 
by either enzymatic trimming [63] or alkaline hydrolysis [13,64]. The resulting pool of fragments of 
randomly distributed lengths is incubated with the target, bound and unbound fragments are recovered 
as separate fractions, and run on a gel (e.g., polyacrylamide) to separate all individual fragments. From 
the patterns that emerge on the gel and the full-length sequence, the minimal binding sequence can be 
deduced. An alternative approach to determine the minimal sequence required for binding is the use of 
fragments of defined lengths obtained by PCR [15] or as synthetic constructs [14], and screening them 
for their binding capacity, e.g., by SPR. To get a better understanding of the aptamer-target interaction, 
nucleotides that are predicted to be important, for instance based on sequence or secondary and tertiary 
structure modeling, could be mutated to other nucleotides and their effect on target binding determined. 
Secondary structure predictions are particularly helpful to identify the smallest DNA or RNA 
molecule still capable of binding the target, and may also reveal the nucleotides that are involved in 
target binding. On the other hand, it is also useful to obtain information on which regions or amino 
acids of the target are actually interacting with the aptamer. To this end, alanine scanning, replacing 
specific amino acids in a protein with alanine, has been successfully used to show that two arginine 
residues in the protease domain of non-structural protein 3 from the Hepatitis C virus are essential for 
aptamer binding [65]. Although successful, this method is very laborious. Hydrogen/deuterium 
exchange in combination with mass spectrometry (HXMS) [66] could provide an alternative method to 
map sites on the protein that interact with the aptamer. Other examples of the investigation of ligand 
specificity are the binding of biotin to an RNA aptamer. Several small molecules, similar to biotin, or 
fragments thereof, were tested for their ability to bind the RNA aptamer. The results suggest that 
binding is not enabled by a single functionality, but rather that several interactions of different parts of 
biotin are required simultaneously [13]. Results of another study, in which the binding capacity of 
various compounds to an ethanolamine-binding aptamer was investigated, showed that the aptamer has 
a preference for only one functionality in the target molecule: either an ethyl- or methylamine group [67]. 
Other advanced analytical techniques are available for investigating aptamer-target interactions. 
ITC is a method used to determine thermodynamic parameters of interactions; the affinity constant 
can, however, also be deduced from ITC data. SPR and QCM can be used to measure the association 
and dissociation rates that underlie the affinity constant of an aptamer-target interaction. SAXS can be 
applied to obtain information on the size and shape of macromolecular structures; like SAXS, DLS 
(also referred to as Quasi-elastic light scattering) can also be used for the determination of particle Int. J. Mol. Sci. 2012, 13  10547 
 
 
sizes and shapes, but it also provides information on the diffusion coefficients in solution. CD is 
particularly useful in determining secondary structures of proteins and aptamer-protein complexes. 
Combining these dedicated analytical techniques can provide useful insights into the aptamer target 
interaction. A recent example for which a combination of these techniques was used (ITC, DLS, NMR 
and SAXS) is the transformation of a cocaine binding aptamer to one that became specific for 
deoxycholic acid, by only replacing a single base pair [19]. 
6. Conclusions and Future Outlook 
Co-crystal structures of aptamer-protein complexes have provided detailed information about the 
interaction between the nucleic acid aptamer and the protein, and can distinguish between electrostatic 
interactions [24] and hydrogen-bonding interactions [28]. Crystal structures are therefore crucial for a 
thorough understanding of the molecular basis of the interaction. Nevertheless, obtaining crystal 
structures of nucleic acid-protein complexes is challenging, because a large number of parameters can 
be varied and numerous conditions need to be screened. In the specific case of aptamer-protein 
complexes, screening becomes even more challenging, because care should be taken that the   
3D-structure of the aptamer remains intact during crystallization experiments. Consequently, the 
nucleic acid parameters (e.g., length, presence or absence of sticky ends) are not easily varied because 
they could disrupt the 3D-structure of the aptamer, which should be avoided. 
Despite the technical advances and the use of high-throughput crystallization methods, it will 
remain a major challenge to obtain aptamer-protein crystals. Improvements in NMR techniques will 
allow larger complexes to be analyzed at lower cost in the near future, providing an appealing 
alternative for crystallography. However, this requires improvements in data analysis routines, because 
data analysis becomes more complicated with increasing molecule size [68]. 
Alternative experimental approaches, such as alanine scanning, ITC, DLS, and SAXS are perhaps 
not as visually appealing as atomic resolution structures, but in combination with computational 
approaches, they may provide very useful information about the molecular basis of the interaction. In 
addition, some of these techniques can provide information on the dynamics of complex formation, 
whereas atomic resolution structures provide a time- and position-averaged image. One promising 
technique for obtaining high-resolution information on aptamer-protein interactions is cryo-electron 
microscopy (cryo-EM). Currently, cryo-EM is often used to study the structure of macromolecular 
assemblies, but its lower limit (~0.1 MDa) [69] is still too high for most of the aptamer-protein 
interactions described today. As technology advances, the lower limit might go down, and cryo-EM 
could become an attractive alternative for X-ray crystallography. Despite the many alternative methods 
to study aptamer-protein interactions, screening numerous crystallization conditions will remain, and 
for the time being, is the only way to obtain atomic resolution structures of aptamer-protein complexes. 
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